Listening...

Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. United States/
    2. Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma

    Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma

    June 29, 2022
    June 29, 2022

    Download the PDF